Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Upholding the Core, Pioneering a New Journey, and Embracing Unstoppable Prosperity | Shenyang Hongqi Pharmaceutical Successfully Held Its 2025 Work Conference
Category:
Company News
Author:
Source:
Add time:2025-02-07 08:26
As the year draws to a close and a new chapter begins, Shenyang Hongqi Pharmaceutical Co., Ltd. successfully convened its 2025 Annual Work Conference on January 19, 2025, in Shenyang. Centered around the theme “Upholding Our Core Values, Forging a New Path, and Embracing Unstoppable Prosperity,” the meeting comprehensively reviewed and summarized the company’s achievements in 2024 while systematically outlining the key priorities for 2025.
Interpretation of Subject Terms
Core Principle:
Building on Hongqi Pharmaceutical’s core strengths in tuberculosis treatment, we are meticulously establishing an integrated “prevention–diagnosis–treatment–management–education” framework to help end the tuberculosis epidemic by 2035.
A New Journey of Refinement:
Pressing forward with determination, we are refining our internal management processes and, leveraging innovation and transformation, are embarking on a strategy of combining generic and innovative drug development. ” The new business model.
Unstoppable:
Purini ® Maximize brand value, drive rapid revenue growth, support public health and clinical practice, and spearhead new directions in industry development.
General Manager’s Work Report
General Manager Liu Wei provided a comprehensive review of the company’s achievements in 2024 across key areas such as production, sales, and R&D, while commending each department for its accomplishments over the past year. Coinciding with the 60th anniversary of Hongqi, the company was pleased to receive approval for five new products and eight product specifications, notably including Hongqi’s first innovative drug. Puruini® Its public listing will bolster the company’s growth. In alignment with the company’s 2025 business objectives, a detailed roadmap for the year has been mapped out, outlining specific initiatives across marketing strategies, R&D project initiation, supply-chain enhancement, and organizational‑system optimization. This provides a clear direction for the company’s development in the coming year and inspires all employees to forge ahead with determination and strive for new heights on this new journey.
Roundtable Forum
At the meeting, representatives of the company’s core workforce and the executive team each put forward practical strategies and insightful perspectives under two themes: “Love the Red Flag, Embrace Innovation, and @the Future” and “Uphold Fundamentals While Innovating, Carrying Forward Sixty Years of Legacy.” The atmosphere was vibrant, with a rich array of compelling viewpoints, collectively ushering in a feast of ideas.
Remarks by the Co-Chairman
General Manager Xiong Yingxin reviewed with everyone the key achievements that Platform One attained in R&D during 2024, and outlined the core objectives behind its establishment. He emphasized that Hongqi’s R&D strategy has always been clear and unwavering. Looking ahead, we aim to further enhance cost‑control capabilities throughout the product development process and leverage the platform’s synergies to overcome the many challenges on the R&D journey. He encouraged all teams within the platform to engage in active communication and collaboration, fostering an open and efficient collaborative environment. General Manager Xiong Yingxin also stressed that, despite the current complex and volatile external environment and internal operational pressures, as Puruini ® The company’s IPO plan is progressing steadily, and Hongqi’s future looks even brighter. We are confident that by focusing on the two core areas of tuberculosis and urology‑andrology, Hongqi will successfully forge a second robust growth trajectory, propelling the company to new heights.
Chairman’s Address
Chairman Yang Bo conveyed the spirit of Fosun Group and Fosun Pharma’s annual meeting, clearly outlining the direction for the coming year. He noted that, looking back at 2024, although Hongqi remained profitable, actual profits fell significantly short of the targeted objectives— a sobering reminder that the pharmaceutical industry is currently at a critical juncture of rapid growth and profound transformation. All employees must maintain a strong sense of crisis and proactively adapt their mindset; only then can we respond with agility and capitalize on emerging opportunities in an ever‑changing environment, confidently navigating the myriad challenges posed by external factors.
Chairman Yang Bo emphasized that, looking ahead to Hongqi’s future development, achieving sustainable growth and realizing the grand vision of building a century‑long legacy for Hongqi are issues that every member of the Hongqi family must ponder deeply. We must remain highly vigilant and clearly recognize that only by keeping generic‑drug costs at a highly competitive level and continuously improving operational efficiency can we secure a firm foothold in the fiercely competitive market, earn our place, and lay a solid foundation for Hongqi’s long‑term development.
Speech by Group Leadership
Wen Deyong, CEO of Fosun Pharma, delivered an important address via remote connection. Mr. Wen highly commended Hongqi’s achievements in implementing the Group’s strategy, praised the Hongqi team for its precision and efficiency in advancing the strategic agenda, and expressed his heartfelt gratitude for the management team’s sustained efforts. Looking ahead to Hongqi’s future development, Mr. Wen noted that the Hongqi brand has already established deep influence and a strong reputation within China; going forward, it should turn its attention to international markets, continue to strengthen its global footprint, and further enhance the brand’s international visibility and competitiveness.
In addition, General Manager Wen expressed high expectations for the younger employees. He encouraged the younger generation to proactively cultivate a sense of ownership, align their personal growth with Hongqi’s development, fully leverage their strengths, and demonstrate courage in taking responsibility and daring to innovate. By shining in their respective roles, they will inject continuous vitality into Hongqi’s future growth. General Manager Wen also stated that, in the face of a complex and ever‑changing external environment, the Group will provide every possible support and assistance to help Hongqi advance steadily on its path forward and consistently achieve outstanding results.
The beating of war drums urges us forward, and the fluttering banners mark the start of our journey. The successful convening of this working conference has laid a solid foundation for the company’s development in 2025. Under the strategic guidance of Chairman Yang Bo, General Manager Liu Wei, and the management team, all members of Hongqi will surely hold hope in their hearts and dreams in their eyes, pressing ahead in pursuit of the light and walking in its radiance, together writing a glorious new chapter for Hongqi Pharmaceutical!
